Leading Microbiology Expert Joins BD Diagnostics in Maryland
SPARKS, Md., Oct. 1, 2012 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today that Paul Bourbeau, Ph.D. has joined the Company as Director, North American Scientific Affairs, BD Diagnostics – Diagnostic Systems.
Dr. Bourbeau brings experience from an impressive career in academics and clinical laboratory practice, most recently serving as Director of Microbiology, Geisinger Medical Laboratories, Danville, PA. In his new role, Dr. Bourbeau will leverage his clinical and scientific expertise to guide the molecular diagnostic and laboratory automation programs. He will be based in the Company's Sparks, MD office.
"We are very pleased to have a leading expert in clinical microbiology and infectious diseases, such as Dr. Bourbeau, joining our team," said Patrick Murray, Ph.D., Worldwide Director of Scientific Affairs, BD Diagnostics – Diagnostic Systems. "His clinical perspective will be a great addition to BD as we launch our BD MAX™ System, BD Viper™ System, and BD Kiestra™ Microbiology Lab Automation platforms."
While at the Geisinger Medical Laboratories, Dr. Bourbeau oversaw the clinical and research programs in Microbiology, served on numerous local and national scientific committees and is currently Associate Editor, Journal of Clinical Microbiology. He received his Ph.D. degree in Microbiology at Temple University School of Medicine and completed postgraduate training in Clinical Microbiology at Hartford Hospital, Hartford, CT.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
SOURCE BD-Becton Dickinson